At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Market Closed 08-14 16:00:00 EDT
1.86
+0.01
+0.54%
盘后1.82
-0.04-2.15%
19:47 EDT
High1.89
Low1.82
Vol36.52K
Open1.88
D1 Closing1.85
Amplitude3.78%
Mkt Cap2.76M
Tradable Cap2.76M
Total Shares1.49M
T/O67.69K
T/O Rate2.46%
Tradable Shares1.48M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Clearmind Advances CMND-100 into Alcohol Use Disorder Patients After Phase I/II Safety Milestone
Clearmind Announces Positive Safety Findings for Cmnd 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part a of Its FDA-Regulated Clinical Trial
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.